EA
PTCT icon

Emerald Advisers’s PTC Therapeutics PTCT Stock Holding History

Emerald Advisers’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-147,280
Closed -$6.57M – 332
2020
Q1 		$6.57M Sell
147,280
-232,508
-61% -$11.7M 0.38% 90
2019
Q4 		$18.2M Buy
379,788
+7,880
+2% +$335K 0.77% 50
2019
Q3 		$12.6M Sell
371,908
-16,102
-4% -$701K 0.59% 71
2019
Q2 		$17.5M Buy
388,010
+88,579
+30% +$3.5M 0.7% 55
2019
Q1 		$11.3M Buy
299,431
+77,928
+35% +$2.62M 0.46% 83
2018
Q4 		$7.6M Sell
221,503
-3,947
-2% -$142K 0.37% 92
2018
Q3 		$10.6M Buy
+225,450
New +$9.33M 0.39% 104
2016
Q1 		– Sell
-137,524
Closed -$4.46M – 329
2015
Q4 		$4.46M Buy
137,524
+115,010
+511% +$3.39M 0.21% 136
2015
Q3 		$601K Buy
+22,514
New +$963K 0.03% 287

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Emerald Advisers's PTCT Position: Q2 2020 in Review

Emerald Advisers sold out of PTC Therapeutics (PTCT) in Q2 2020, closing a stake of 147,280 shares — an estimated $6.57M sold.

Emerald Advisers first reported a position in PTCT in Q3 2015 and held it in 9 quarters. The position peaked at $18.2M in Q4 2019. 202 funds tracked by Wall St. Rank hold PTCT as of Q2 2020.

  • Emerald Advisers reported no remaining PTC Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Emerald Advisers sold 147,280 PTC Therapeutics shares in Q2 2020, an estimated $6.57M.
  • Emerald Advisers first reported a position in PTC Therapeutics in Q3 2015 and held it in 9 quarters.
  • Emerald Advisers's PTC Therapeutics position peaked at $18.2M in Q4 2019.
  • 202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2020.

Based on Emerald Advisers's 13F filing for Q2 2020, filed 28 Jul 2020.